DNA methylation is well-known to be associated with ovarian cancer (OC) and has great potential to serve as a biomarker in monitoring response to therapy and for disease screening. The purpose of this study was to investigate methylation of HNF1B and GATA4 and correlate detected methylation with clinicopathological characteristic of OC patients. The study group consisted of 64 patients with OC and 35 control patients. To determine the most important sites of HNF1B and GATA4, we used next-generation sequencing. For further confirmation of detected methylation of selected regions, we used high-resolution melting analysis and methylation-specific real-time polymerase chain reaction (PCR). Selected regions of HNF1B and GATA4 were completely methylation free in all control samples, whereas methylation-positive pattern was observed in 32.8% (HNF1B) and 45.3% (GATA4) of OC samples. Evaluating both genes together, we were able to detect methylation in 65.6% of OC patients. We observed a statistically significant difference in HNF1B methylation between samples with different stages of OC. We also detected subtype specific methylation in GATA4 and a decrease of methylation in late stages of OC. The combination of unmethylated HNF1B and methylated GATA4 was associated with longer overall survival. In our study, we employed innovative approach of methylation analysis of HNF1B and GATA4 to search for possible epigenetic biomarkers. We confirmed the significance of the HNF1B and GATA4 hypermethylation with emphasis on the need of selecting the most relevant sites for analysis. We suggest selected CpGs to be further examined as a potential positive prognostic factor.

Department of Clinical Genetics University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

Department of Obstetrics and Gynecology Charles University Faculty of Medicine and University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

Institute of Clinical Biochemistry and Diagnostics Charles University Faculty of Medicine and University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

The Fingerland Department of Pathology Charles University Faculty of Medicine and University Hospital Hradec Kralove 500 05 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Kurman R., Carcangiu M.L., Herrington C.S., Young R.H. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. IARC Press; Lyon, France: 2014.

Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., Forman D., Bray F. Cancer incidence and mortality patterns in europe: Estimates for 40 countries in 2012. Eur. J. Cancer. 2013;49:1374–1403. doi: 10.1016/j.ejca.2012.12.027. PubMed DOI

Longuespée R., Boyon C., Desmons A., Vinatier D., Leblanc E., Farré I., Wisztorski M., Ly K., D’Anjou F., Day R., et al. Ovarian cancer molecular pathology. Cancer Metastasis Rev. 2012;31:713–732. doi: 10.1007/s10555-012-9383-7. PubMed DOI

Barton C.A., Hacker N.F., Clark S.J., O’Brien P.M. DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment. Gynecol. Oncol. 2008;109:129–139. doi: 10.1016/j.ygyno.2007.12.017. PubMed DOI

Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002;3:415–428. PubMed

Graham J.S., Kaye S.B., Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer. 2009;45:1129–1136. doi: 10.1016/j.ejca.2009.01.003. PubMed DOI

Koukoura O., Spandidos D.A., Daponte A., Sifakis S. DNA methylation profiles in ovarian cancer: Implication in diagnosis and therapy (review) Mol. Med. Rep. 2014;10:3–9. doi: 10.3892/mmr.2014.2221. PubMed DOI PMC

Zhang Q., Burdette J.E., Wang J.-P. Integrative network analysis of TCGA data for ovarian cancer. BMC Syst. Biol. 2014;8:1–18. doi: 10.1186/s12918-014-0136-9. PubMed DOI PMC

Zheng R., Blobel G.A. GATA transcription factors and cancer. Genes Cancer. 2010;1:1178–1188. doi: 10.1177/1947601911404223. PubMed DOI PMC

Wittenberger T., Sleigh S., Reisel D., Zikan M., Wahl B., Alunni-Fabbroni M., Jones A., Evans I., Koch J., Paprotka T., et al. DNA methylation markers for early detection of women’s cancer: Promise and challenges. Epigenomics. 2014;6:311–327. doi: 10.2217/epi.14.20. PubMed DOI

Earp M.A., Cunningham J.M. DNA methylation changes in epithelial ovarian cancer histotypes. Genomics. 2015;106:311–321. doi: 10.1016/j.ygeno.2015.09.001. PubMed DOI PMC

Dong A., Lu Y., Lu B. Genomic/epigenomic alterations in ovarian carcinoma: Translational insight into clinical practice. J. Cancer. 2016;7:1441–1451. doi: 10.7150/jca.15556. PubMed DOI PMC

Harries L.W., Perry J.R., McCullagh P., Crundwell M. Alterations in LMTK2, MSMB and HNF1B gene expression are associated with the development of prostate cancer. BMC Cancer. 2010;10:315. doi: 10.1186/1471-2407-10-315. PubMed DOI PMC

Setiawan V.W., Haessler J., Schumacher F., Cote M.L., Deelman E., Fesinmeyer M.D., Henderson B.E., Jackson R.D., Vöckler J.-S., Wilkens L.R., et al. HNF1B and endometrial cancer risk: Results from the PAGE study. PLoS ONE. 2012;7:e30390. doi: 10.1371/journal.pone.0030390. PubMed DOI PMC

Tsuchiya A., Sakamoto M., Yasuda J., Chuma M., Ohta T., Ohki M., Yasugi T., Taketani Y., Hirohashi S. Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1β as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003;163:2503–2512. doi: 10.1016/S0002-9440(10)63605-X. PubMed DOI PMC

Yu D.-D., Guo S.-W., Jing Y.-Y., Dong Y.-L., Wei L.-X. A review on hepatocyte nuclear factor-1β and tumor. Cell Biosci. 2015;5:1–8. doi: 10.1186/s13578-015-0049-3. PubMed DOI PMC

Kao Y.C., Lin M.C., Lin W.C., Jeng Y.M., Mao T.L. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells. Histopathology. 2012;61:760–768. doi: 10.1111/j.1365-2559.2012.04267.x. PubMed DOI

Silva T.D., Vidigal V.M., Felipe A.V., de Lima J.M., Neto R.A., Saad S.S., Forones N.M. DNA methylation as an epigenetic biomarker in colorectal cancer. Oncol. Lett. 2013;6:1687–1692. PubMed PMC

Tommasi S., Karm D.L., Wu X., Yen Y., Pfeifer G.P. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res. BCR. 2009;11:R14. doi: 10.1186/bcr2233. PubMed DOI PMC

Shen H., Fridley B.L., Song H., Lawrenson K., Cunningham J.M., Ramus S.J., Cicek M.S., Tyrer J., Stram D., Larson M.C., et al. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat. Commun. 2013;4:1628. doi: 10.1038/ncomms2629. PubMed DOI PMC

Terasawa K., Toyota M., Sagae S., Ogi K., Suzuki H., Sonoda T., Akino K., Maruyama R., Nishikawa N., Imai K., et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br. J. Cancer. 2006;94:914–921. doi: 10.1038/sj.bjc.6602984. PubMed DOI PMC

Akiyama Y., Watkins N., Suzuki H., Jair K.W., van Engeland M., Esteller M., Sakai H., Ren C.Y., Yuasa Y., Herman J.G., et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol. Cell. Biol. 2003;23:8429–8439. doi: 10.1128/MCB.23.23.8429-8439.2003. PubMed DOI PMC

Guo M., Akiyama Y., House M.G., Hooker C.M., Heath E., Gabrielson E., Yang S.C., Han Y., Baylin S.B., Herman J.G., et al. Hypermethylation of the GATA genes in lung cancer. Clin. Cancer Res. 2004;10:7917–7924. doi: 10.1158/1078-0432.CCR-04-1140. PubMed DOI

Wakana K., Akiyama Y., Aso T., Yuasa Y. Involvement of GATA-4/-5 transcription factors in ovarian carcinogenesis. Cancer Lett. 2006;241:281–288. doi: 10.1016/j.canlet.2005.10.039. PubMed DOI

Montavon C., Gloss B.S., Warton K., Barton C.A., Statham A.L., Scurry J.P., Tabor B., Nguyen T.V., Qu W., Samimi G., et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol. Oncol. 2012;124:582–588. doi: 10.1016/j.ygyno.2011.11.026. PubMed DOI

Chmelarova M., Dvorakova E., Spacek J., Laco J., Palicka V. Importance of promoter methylation of GATA4 gene in epithelial ovarian cancer. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czechoslovakia. 2013;157:294–297. doi: 10.5507/bp.2013.079. PubMed DOI

Kurman R.J., Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am. J. Surg. Pathol. 2010;34:433–443. doi: 10.1097/PAS.0b013e3181cf3d79. PubMed DOI PMC

A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122 cases of high-grade serous ovarian carcinoma

Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours

HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study

Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach